For MM treatment, different strategies have been developed for CAR T-cells to target dual antigens including BCMA, such as dual CAR T-cell combination infusion of anti-CD19 and anti-BCMA CAR T-cells, BCMA-CS1 compound CAR (cCAR) T-cells targeting both BCMA and CS1, BCMA and CD19 bispecific CAR-T, and APRIL-CAR T-cells targeting both BCMA and TACI. This evidence concerns the gene SLAMF7 and Miyoshi myopathy.